2025
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy
Buchbinder E, Lotze M, Margolin K, Amaria R, Sarnaik A, Seery V, Eroglu Z, Khaddour K, Warner A, Kluger H, Sznol M, Atkins M, Mcdermott D, Silk A. Role of high-dose interleukin-2 for melanoma in the age of cellular therapy. Journal For ImmunoTherapy Of Cancer 2025, 13: e011119. PMID: 40447314, PMCID: PMC12128428, DOI: 10.1136/jitc-2024-011119.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesTIL infusionInterleukin-2Cellular therapyHigh-dose bolus IL-2High-dose interleukin-2Renal cell carcinoma patientsBolus interleukin-2Cytokine-related toxicitiesExcellent organ functionIL-2 monotherapyIL-2 toxicityLife-threatening side effectsPartial tumor regressionCell carcinoma patientsInterleukin-2 dosesT cell productionTreatment of patientsNational Cancer InstituteAdvanced melanomaTumor regressionCarcinoma patientsAdjunctive therapyInpatient administrationSide effects
2021
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal Of Clinical Oncology 2021, 44: 495-501. PMID: 34432667, DOI: 10.1097/coc.0000000000000849.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRCC brain metastasesBrain metastasesRenal cell carcinomaStereotactic radiosurgeryOverall survivalUse of ICIsCentral nervous system toxicityRenal cell carcinoma patientsImpact of immunotherapyLocal control outcomesMedian overall survivalCell carcinoma patientsKaplan-Meier curvesNervous system toxicityBetter median OSLog-rank testMann-Whitney U testMargin doseMedian OSNonimmunotherapy groupSRS doseCheckpoint inhibitorsImmunotherapy groupCarcinoma patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply